The stock of Matinas BioPharma Holdings Inc. (AMEX:MTNB) decreased by $0.0 on Tuesday to at $0.18, up 4.25 percent. The last five days have seen an average of 550,399 shares of common stock traded. 13 times new highs were reached in the current year, with a fall of -$0.3167. The average number of shares traded over the last 20 days was 1,094,705, while the average volume over the last 50 days totaled 708,964.
MTNB stock dropped -47.43% since last month. On 08/10/23, the company’s shares reached a one-month low of $0.1103. The stock touched a high of $0.89 on 04/20/23, after rallying from a low of $0.11 in 52 weeks. The price of MTNB stock has declined by -63.20% or -$0.3167 this year, reaching a new high 13 times. Still, the stock price is down -79.33% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
Beta for the stock is 2.06. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 11.82, the price-to-book (PB) ratio of 1.42.
Financial Health
For the recent quarter, Matinas BioPharma Holdings Inc.’s quick ratio was 9.30, while its current ratio was 9.30, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $27.78 million and revenue of $3.19 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. MTNB’s return on assets (ROA) during the last 12 months has been -50.20%. In the meantime, the return on equity (ROE) for the last 12 months was -60.90%.
Earnings Surprise
EBITDA was -$5.9 million for the quarter. At the end of Matinas BioPharma Holdings Inc.’s most recent quarter, its liabilities totaled 6.17 million, while its total debt was $3.85 million. Equity owned by shareholders amounts to $217.26 million.
Technical Picture
Here’s a quick look at Matinas BioPharma Holdings Inc.’s (MTNB) price momentum from a technical perspective. As of 28 August, the RSI 9-day stood at 36.60%, suggesting the stock is Neutral, with a 114.74% historical volatility rate.
The stochastic %K and %D were 39.41% and 35.12% respectively, while the average true range (ATR) was 0.0299. Based on the 14-day stochastic reading of 53.44%, the RSI (14) reading is 33.58%. On the 9-day MACD Oscillator, the stock is at 0.0090, and the 14-day reading is at 0.0109.
Analyst Ratings
Matinas BioPharma Holdings Inc. (AMEX: MTNB) was downgraded by Piper Sandler to a a Neutral rating in its latest research report. The stock was previously rated as a an Overweight. Analysts have assigned Matinas BioPharma Holdings Inc. (MTNB) an Buy rating. MTNB is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 1 other recommend it as a buy.
What is MTNB’s price target for the next 12 months?
The current consensus forecast for the stock is between $3.00 and $3.00, with a median target price of $3.00. In analyzing these forecasts, the average price target given by analysts for Matinas BioPharma Holdings Inc. (MTNB) is $3.00.
